参考文献
- Sieper J, Rudwaleit M, Khan MA,
Braun J: Concepts and epidemiology of spondyloarthritis. Best Pract
Res Clin Rheumatol 2006, 20:401–417.
- Braun J, Sieper J: Ankylosing
spondylitis. Lancet 2007,369:1379–1390.
- Rudwaleit M, Metter A, Listing J,
et al.: Inflammatory back pain in ankylosing spondylitis: a
reassessment of the clinical history for application as
classification and diagnostic criteria. Arthritis Rheum 2006,
54:569–578.
- van der Linden SM, Valkenburg HA,
de Jongh BM, Cats A: The risk of developing ankylosing spondylitis
in HLA-B27 positive individuals. A comparison of relatives of
spondylitis patients with the general population. Arthritis Rheum
1984, 27:241–249.
- Rudwaleit M, Khan MA, Sieper J: The
challenge of diagnosis and classification in early ankylosing
spondylitis: do we need new criteria? Arthritis Rheum 2005,
52:1000–1008.
- Feldtkeller E, Khan MA, van der
Heijde D, et al.: Age at disease onset and diagnosis delay in
HLA-B27 negative vs. positive patients with ankylosing spondylitis.
Rheumatol Int 2003, 23:61–66.
- Brandt HC, Spiller I, Song IH, et
al.: Performance of referral recommendations in patients with
chronic back pain and suspected axial spondyloarthritis. Ann Rheum
Dis 2007, 66:1479–1484.
- Song IH, Poddubnyy DA, Rudwaleit M,
Sieper J: Benefits and risks of ankylosing spondylitis treatment
with nonsteroidal antiinflammatory drugs. Arthritis Rheum 2008,
58:929–938.
- Braun J, Brandt J, Listing J, et
al.: Treatment of active ankylosing spondylitis with infliximab: a
randomised controlled multicentre trial. Lancet 2002,
359:1187–1193.
- Davis JC Jr, Van Der Heijde D,
Braun J, et al.: Recombinant human tumor necrosis factor receptor
(etanercept) for treating ankylosing spondylitis: a randomized,
controlled trial. Arthritis Rheum 2003, 48:3230–3236.
- van der Heijde D, Kivitz A, Schiff
MH, et al.: Efficacy and safety of adalimumab in patients with
ankylosing spondylitis: results of a multicenter, randomized,
double-blind, placebocontrolled trial. Arthritis Rheum 2006,
54:2136–2146.
- 12•• Braun J, Landewe R, Hermann
KG, et al.: Major reduction in spinal inflammation in patients with
ankylosing spondylitis after treatment with infliximab: results of
a multicenter, randomized, double-blind, placebo-controlled
magnetic resonance imaging study. Arthritis Rheum 2006,
54:1646–1652. [ This study clearly illustrates the successful
treatment of inflammatory lesions as detected by MRI in the spine
of AS patients treated with TNF-blockers but not in the placebo
group. ]
- Calin A, Mackay K, Santos H, Brophy
S: A new dimension to outcome: application of the Bath Ankylosing
Spondylitis Radiology Index. J Rheumatol 1999,
26:988–992.
- Creemers MC, Franssen MJ, van't Hof
MA, et al.: Assessment of outcome in ankylosing spondylitis: an
extended radiographic scoring system. Ann Rheum Dis 2005,
64:127–129.
- van der Heijde D, Landewé R, van
der Linden S: How should treatment effect on spinal radiographic
progression in patients with ankylosing spondylitis be measured?
Arthritis Rheum 2005, 52:1979–1985.
- Braun J, Sieper J, Bollow M:
Imaging of sacroiliitis. Clin Rheumatol 2000, 19:51–57.
- Hermann KG, Althoff CE, Schneider
U, et al.: Spinal changes in patients with spondyloarthritis:
comparison of MR imaging and radiographic appearances.
Radiographics 2005, 25:559–569.
- Maksymowych WP, Inman RD, Salonen
D, et al.: Spondyloarthritis research Consortium of Canada magnetic
resonance imaging index for assessment of sacroiliac joint
inflammation in ankylosing spondylitis. Arthritis Rheum 2005,
53:703–709.
- Haibel H, Rudwaleit M, Brandt HC,
et al.: Adalimumab reduces spinal symptoms in active ankylosing
spondylitis: clinical and magnetic resonance imaging results of a
fifty-twoweek open-label trial. Arthritis Rheum 2006,
54:678–681.
- Maksymowych WP, Dhillon SS, Park R,
et al.: Validation of the spondyloarthritis research consortium of
Canada magnetic resonance imaging spinal inflammation index: is it
necessary to score the entire spine? Arthritis Rheum 2007,
57:501–507.
- Weber U, Pfirrmann CW, Kissling RO,
et al.: Whole body MR imaging in ankylosing spondylitis: a
descriptive pilot study in patients with suspected early and active
confirmed ankylosing spondylitis. BMC Musculoskelet Disord 2007,
8:20.
- Althoff CE, Appel H, Rudwaleit M,
et al.: Whole-body MRI as a new screening tool for detecting axial
and peripheral manifestations of spondyloarthritis. Ann Rheum Dis
2007, 66:983–985.
- Appel H, Hermann KG, Althoff CE, et
al.: Whole-body magnetic resonance imaging evaluation of widespread
inflam¬matory lesions in a patient with ankylosing spondylitis
before and after 1 year of treatment with infliximab. J Rheumatol
2007, 34:2497–2498.
- Weber U, Kissling RO, Holder J:
Advances in musculoskeletal imaging and their clinical utility in
the early diagnosis of spondyloarthritis. Curr Rheumatol Rep 2007,
9:353–360.
- Weber U, Pfirrmann CWA, Kissling
RO, et al.: Early spondyloarthritis in HLA-B27 positive monozygotic
twin pair: A highly concordant onset, sites of involvement, and
disease course. J Rheumatol 2008, 35:1464–1466.
- Poole AR: The histopathology of
ankylosing spondylitis: are there unifying hypotheses? Am J Med Sci
1998, 316:228–233.
- Maksymowych WP: Ankylosing
spondylitis--at the interface of bone and cartilage. J Rheumatol
2000, 27:2295–2301.
- McGonagle D, Gibbon W, Emery P:
Classification of inflammatory arthritis by enthesitis. Lancet
1998, 352:1137–1140.
- Ball J: Pathology and pathogenesis.
In: Ankylosing spondylitis. Edited by Moll JM. Edinburgh: Churchill
Livingstone; 1980:96–112.
- Cruickshank B: Lesions of
cartilaginous joints in ankylosing spondylitis. J Pathol Bacteriol
1956, 71:73–84.
- Bywaters EGL, Olsen E: A case of
early ankylosing spondylitis with fatal secondary amyloidosis:
demonstrated at the Royal Postgraduate Medical School. BMJ 1968,
2:412–416.
- Francois RJ, Gardner DL, Degrave
EJ, Bywaters EG: Histopathologic evidence that sacroiliitis in
ankylosing spondylitis is not merely enthesitis. Arthritis Rheum
2000, 43:2011–2024.
- Braun J, Bollow M, Neure L, et al.:
Use of immuno¬histologic and in situ hybridization techniques in
the examination of sacroiliac joint biopsy specimens from patients
with ankylosing spondylitis. Arthritis Rheum 1995,
38:499–505.
- Savill DL: The manubrio-sternal
joint in ankylosing spondylitis. J Bone Joint Surg Br 1951,
33:56–64.
- 35.• Appel H, Kuhne M, Spiekermann
S, et al.: Immunohisto¬chemical analysis of hip arthritis in
ankylosing spondylitis: evaluation of the bone-cartilage interface
and subchondral bone marrow. Arthritis Rheum 2006, 54:1805–1813. [
Immunohistochemical analysis of a larger cohort of AS patients,
which defines the typical histologic features of acute inflammatory
lesions in AS, suggesting that cartilage might be the primary
target of the immune response. ]
- Braun J, Bollow M, Eggens U, et
al.: Use of dynamic mag¬netic resonance imaging with fast imaging
in the detection of early and advanced sacroiliitis in
spondylarthropathy patients. Arthritis Rheum 1994,
37:1039–1045.
- Bollow M, Fischer T, Reisshauer H,
et al.: Quantitative analyses of sacroiliac biopsies in
spondyloarthropathies: T cells and macrophages predominate in early
and active sacroiliitis—cellularity correlates with the degree of
enhance¬ment detected by magnetic resonance imaging. Ann Rheum Dis
2000, 59:135–140.
- Golder W, Karberg K, Sieper J:
Fluoroscopy-guided applica¬tion of corticosteroids for local
control of manubriosternal joint pain in patients with
spondyloarthropathies. Clin Rheumatol 2004, 23:481–484.
- McGonagle D, Gibbon W, O´Connor P,
et al.: Characteristic magnetic resonance imaging entheseal changes
of knee synovitis in spondylarthropathy. Arthritis Rheum 1998,
41:694–700.
- Lambert RG, Dhillon SS, Jhangri GS,
et al.: High prevalence of symptomatic enthesopathy of the shoulder
in ankylosing spondylitis: deltoid origin involvement constitutes a
hallmark of disease. Arthritis Rheum 2004, 51:681–690.
- Appel H, Kuhne M, Spiekermann S, et
al.: Immunohistologic analysis of zygapophyseal joints in patients
with ankylosing spondylitis. Arthritis Rheum 2006,
54:2845–2851.
- Appel H, Loddenkemper C,
Grozdanovic Z, et al.: Correlation of histopathological findings
and magnetic resonance imaging in the spine of patients with
ankylosing spondylitis. Arthritis Res Ther 2006,
8:R143.
- Brandt J, Haibel H, Cornely D, et
al.: Successful treatment of active ankylosing spondylitis with the
anti-tumor necrosis factor alpha monoclonal antibody infliximab.
Arthritis Rheum 2000, 43:1346–1352.
- Appel H, Loddenkemper C, Heydrich
R, et al.: Immuno¬histochemical analysis of osteoblasts in
zygapophyseal joints of patients with anyklosing spondylitis reveal
repair functions similar to osteoarthritis. Ann Rheum Dis 2008,
67(Suppl II):59.
- de Vlam K, Lories RJ, Luyten FP:
Mechanisms of pathologic new bone formation. Curr Rheumatol Rep
2006, 8:332–337.
- 46.• Lories RJ, Derese I, de Bari
C, Luyten FP: Evidence for uncoupling of inflammation and joint
remodeling in a mouse model of spondylarthritis. Arthritis Rheum
2007, 56:489–497. [ This interesting murine model illustrates that
new bone formation can occur independently of inflammation. The
authors hypothesize that enchondral ossification is of great
importance for new bone formation in AS. ]
- Ball J: Enthesopathy of rheumatoid
and ankylosing spondylitis. Ann Rheum Dis 1971,
30:213–223.
- Zwerina J, Tuerk B, Redlich K, et
al.: Imbalance of local bone metabolism in inflammatory arthritis
and its reversal upon tumor necrosis factor blockade: direct
analysis of bone turnover in murine arthritis. Arthritis Res Ther
2006, 8:R22.
- Walsh NC, Manning CA, Boch JA, et
al.: Wnt signalling antagonists are candidates for the suppression
of osteoblast differentiation in inflammatory arthritis. Arthritis
Rheum 2006, 54(Suppl):S511.
- 50.•• Diarra D, Stolina M, Polzer
K, et al.: Dickkopf-1 is a master regulator of joint remodeling.
Nat Med 2007, 13:156–163. [ This manuscript is an important
contribution to the understanding of the molecular basis of the
cross-talk between inflammation and new bone formation in
inflammatory joint diseases. Cytokines such as TNF-α inhibit
osteoblast activity, which is stimulated after disappearance of
inflammation. ]
- Lacey DL, Timms E, Tan HL, et al.:
Osteoprotegerin ligand is a cytokine that regulates osteoclast
differentiation and activation. Cell 1998, 93:165–176.
- Sieper J, Appel H, Braun J,
Rudwaleit M: Critical appraisal of assessment of structural damage
in ankylosing spondylitis: implications for treatment outcomes.
Arthritis Rheum 2008, 58:649–656.
- Maksymowych WP, Chiowchanwisawakit
P, Clare T, Lambert RG: Inflammatory lesions of the spine on MRI
predict the development of new syndesmophytes in ankylosing
spondy¬litis: Evidence for coupling between inflammation and new
bone formation. Ann Rheum Dis 2008, 67(Suppl II):130.
- Baraliakos X, Listing J, Rudwaleit
M, et al.: Evidence for a link between inflammation and new bone
formation in ankylosing spondylitis—a detailed analysis. Ann Rheum
Dis 2008, 67(Suppl II):130.
- Van der Heijde D, Landewe R,
Baraliakos X, et al.: MRI inflammation of the vertebral unit (VU)
only marginally contributes to new syndesmophyte formation in that
unit: a multi-level analysis. Ann Rheum Dis 2008, 67(Suppl
II):130.
- Schett G, Landewé R, van der Heijde
D: Tumour necrosis factor blockers and structural remodelling in
ankylosing spondylitis: what is reality and what is fiction? Ann
Rheum Dis 2007, 66:709–711.
- Rudwaleit M, Schwarzlose S, Hilgert
ES, et al.: Magnetic resonance imaging (MRI) in predicting a major
clinical response to anti-TNF-treatment in ankylosing spondylitis.
Ann Rheum Dis 2007, (Nov 15 Epub ahead of print).
- Haibel H, Rudwaleit M, Listing J,
et al.: Efficacy of adali¬mumab in the treatment of axial
spondylarthritis without radiographically defined sacroiliitis:
Results of a twelve-week randomized, double-blind,
placebo-controlled trial followed by an open-label extension up to
week fifty-two. Arthritis Rheum 2008, 58:1981–1991.
- Barkham N, Keen HI, Coates LC, et
al.: A randomized controlled trial of infliximab shows clinical and
MRI efficacy in HLA-B27 positive very early ankylosing spondylitis.
Ann Rheum Dis 2008, 67(Suppl II):382.
- Sieper J, Baraliakos X, Listing J,
et al.: Persistent reduction of spinal inflammation as assessed by
magnetic resonance imaging in patients with ankylosing spondylitis
after 2 yrs of treatment with the anti-tumour necrosis factor agent
infliximab. Rheumatology (Oxford) 2005, 44:1525–1530.
- Braun J, Baraliakos X, Listing J,
et al.: Persistent clinical efficacy and safety of anti-tumour
necrosis factor alpha therapy with infliximab in patients with
ankylosing spon¬dylitis over 5 years: evidence for different types
of response. Ann Rheum Dis 2008, 67:340–345.
- Heiberg MS, Koldingsnes W,
Mikkelsen K, et al.: The comparative one-year performance of
anti-tumor necrosis factor alpha drugs in patients with rheumatoid
arthritis, psoriatic arthritis, and ankylosing spondylitis: results
from a longitudinal, observational, multicenter study. Arthritis
Rheum 2008, 59:234–240.
- 63.•• van der Heijde D, Landewé R,
Einstein S, et al.: Radio¬graphic progression of ankylosing
spondylitis after up to two years of treatment with etanercept.
Arthritis Rheum 2008, 58:1324–1331. [ Researchers found that in 257
etanercept-treated AS patients, despite successful treatment of
signs and symptoms of inflammation, further minor growth of
syndesmophytes was observed without significant differences to a
TNF-blocker–naïve control cohort. ]
- van der Heijde D, Landewe R,
Deoadar A, et al.: Radio¬graphic progression in patients with
ankylosing spondylitis after 2 years of treatment not inhibited
with infliximab. Ann Rheum Dis 2007, 66(Suppl II):85–86;
OP0111.
- Braun J, Han C, Kellner H, et al.:
Infliximab improves spinal mobility in patients with ankylosing
spondylitis: two year findings from the ASSERT clinical trial. Ann
Rheum Dis 2007, 66(Suppl II):390.
- Braun J, Sieper J: What is the most
important outcome parameter in ankylosing spondylitis ?
Rheumatology 2008 (in press).
- Lories RJ, Derese I, Luyten FP:
Modulation of bone morpho¬genetic protein signaling inhibits the
onset and progression of ankylosing enthesitis. J Clin Invest 2005,
115:1571–1579.
- Lories RJ, Daans M, Derese I, et
al.: Noggin haploinsuffi¬ciency differentially affects tissue
responses in destructive and remodeling arthritis. Arthritis Rheum
2006, 54:1736–1746.
- Wanders A, Heijde D, Landewé R, et
al.: Nonsteroidal antiinflammatory drugs reduce radiographic
progression in patients with ankylosing spondylitis: a randomized
clinical trial. Arthritis Rheum 2005, 52:1756–1765.
|